The global ovarian cancer drugs market was valued at $1.8 Billion in 2017 and is forecast to grow at a modest 29.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $X.5 Billion.
Ovarian cancer is a group of diseases that originate in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome raise ovarian cancer risk.
Around 20,000 women get ovarian cancer each year in U.S. alone. However, it counts only 3% of all forms of cancer to women. We are noticing 11 new cases of ovarian cancer among 100,000 women in U.S. and 6.7 deaths.
“Optimal Price Point (OPP) for Ovarian Cancer Drugs”
Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the ovarian cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Ovarian Cancer Drugs Market by “Disease Type”
We have segmented the Ovarian Cancer Drugs market into Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma. Ovarian epithelial tumors arise from the simple cuboidal surface epithelium of the ovary and account for 90% of all ovarian cancer. Epithelial ovarian cancer can be further segmented into serous, endometrioid, clear cell, mucinous and undifferentiated or unclassifiable. Ovarian germ cell tumor can cause swelling of the abdomen or vaginal bleeding after menopause. We are observing maximum development work on Epithelial Ovarian Cancer Drugs and will continue during the forecasting period.
Ovarian Cancer Drugs Market by “Treatment Categories”
We have segmented the Ovarian Cancer Drugs market by treatment into Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy. We are observing newer biologic into immunotherapy shaping the Ovarian Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.
Ovarian Cancer Drugs Market by “Drug Class”
We have broadly segmented the market as PARP inhibitors, PD-L1 inhibitors, Angiogenesis Inhibitors and Others. Some of the major drugs are Olaparib (Astra Zeneca), Pembrolizumab, Bevacizumab (Avastin). However, we have considered following ovarian cancer drugs while determining the market size- Alkeran (Melphalan), Avastin (Bevacizumab), Bevacizumab, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Dox-SL (Doxorubicin Hydrochloride Liposome), DOXIL (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), LipoDox (Doxorubicin Hydrochloride Liposome), Lynparza (Olaparib), Melphalan, Niraparib Tosylate Monohydrate, Olaparib, Paclitaxel, Rubraca (Rucaparib Camsylate), Rucaparib Camsylate, Taxol (Paclitaxel), Thiotepa, Topotecan Hydrochloride, Zejula (Niraparib Tosylate Monohydrate)
Ovarian Cancer Drugs Market by “Distribution Channel”
We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.
North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND. Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.
With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.
“Competitive Landscape” and “Merger & Acquisition Insights”
The key market participants include AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Kazia Therapeutics Ltd, Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, Tesaro, and Clovis Oncology. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for ovarian cancer significantly. We are observing a new drug development for ovarian cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,
- Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
- Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.
Ovarian Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)
- Epithelial Ovarian Tumors
- Ovarian Germ Cell Tumors
- Ovarian Stromal Tumors
- Primary Peritoneal Carcinoma
Ovarian Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)
- Radiation therapy
- Autologous stem-cell transplantation
- Targeted Therapy
Ovarian Cancer Drugs Market by Drug Class (Revenue, Million, 2014 – 2025)
- PARP inhibitors
- PD-L1 inhibitors
- Angiogenesis Inhibitors
Ovarian Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)
- Drug Store
- Specialty Pharmacy
Ovarian Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
Ovarian Cancer Drugs Market, Ovarian Cancer Drugs Market Analytics, Ovarian Cancer Drugs Market Share, Ovarian Cancer Drugs Market Research, Ovarian Cancer Drugs Market Forecast, Ovarian Cancer Drugs Market Insight, Ovarian Cancer Drugs Market Trend, Ovarian Cancer Drugs Market Value,Ovarian Cancer Drugs Market Size, Ovarian Cancer Drugs Market Analysis, Ovarian Cancer Drugs Market Survey